RU2011109880A - METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING THE ONBECOMMARKER UBE2C (OPTIONS) AND KIT FOR ITS IMPLEMENTATION - Google Patents

METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING THE ONBECOMMARKER UBE2C (OPTIONS) AND KIT FOR ITS IMPLEMENTATION Download PDF

Info

Publication number
RU2011109880A
RU2011109880A RU2011109880/10A RU2011109880A RU2011109880A RU 2011109880 A RU2011109880 A RU 2011109880A RU 2011109880/10 A RU2011109880/10 A RU 2011109880/10A RU 2011109880 A RU2011109880 A RU 2011109880A RU 2011109880 A RU2011109880 A RU 2011109880A
Authority
RU
Russia
Prior art keywords
ube2c
diagnosis
bladder cancer
protein
real
Prior art date
Application number
RU2011109880/10A
Other languages
Russian (ru)
Other versions
RU2468088C1 (en
Inventor
Анастасия Александровна Заболотнева (RU)
Анастасия Александровна Заболотнева
Петр Викторович Шегай (RU)
Петр Викторович Шегай
Нуршат Минуллаевич Гайфуллин (RU)
Нуршат Минуллаевич Гайфуллин
Игорь Георгиевич Русаков (RU)
Игорь Георгиевич Русаков
Борис Яковлевич Алексеев (RU)
Борис Яковлевич Алексеев
Антон Александрович Буздин (RU)
Антон Александрович Буздин
Original Assignee
Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН (RU)
Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН (RU), Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН filed Critical Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН (RU)
Priority to RU2011109880/10A priority Critical patent/RU2468088C1/en
Publication of RU2011109880A publication Critical patent/RU2011109880A/en
Application granted granted Critical
Publication of RU2468088C1 publication Critical patent/RU2468088C1/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

1. Способ диагностики рака мочевого пузыря методом ПЦР в режиме реального времени, включающий получение биоматериала и выделение РНК, синтез кДНК на матрице РНК, нормирование концентрации кДНК UBE2C по контрольному гену, проведение количественной ПЦР-амплификации фрагмента гена UBE2C и проведение диагностики путем определения количества амплифицированного фрагмента ДНК UBE2C для образца биоматериала. ! 2. Набор для диагностики рака мочевого пузыря по п.1 методом ПЦР в реальном времени, включающий праймеры с последовательностью SEQ ID NO: 1 и 2 при их молярном соотношении 1:1. ! 3. Способ диагностики рака мочевого пузыря методом иммуноферментного анализа, включающий получение образцов мочи и крови от пациента, выделение смеси белковых компонентов мочи и крови, проведение реакции иммуноферментного анализа с моноклональными и/или поликлональными антителами и/или их фрагментами против рекомбинантного белка UBE2C и/или его уникальных фрагментов длиной свыше 8 аминокислот и проведение диагностики путем определения содержания белка UBE2C в исследуемых образцах. 1. A method for the diagnosis of bladder cancer by real-time PCR, including biomaterial production and RNA isolation, cDNA synthesis on an RNA matrix, normalization of the concentration of UBE2C cDNA by the control gene, quantitative PCR amplification of a fragment of the UBE2C gene and diagnosis by determining the amount of amplified UBE2C DNA fragment for a biomaterial sample. ! 2. The kit for the diagnosis of bladder cancer according to claim 1 by real-time PCR, including primers with the sequence of SEQ ID NO: 1 and 2 with a molar ratio of 1: 1. ! 3. A method for the diagnosis of bladder cancer by enzyme immunoassay, which includes obtaining urine and blood samples from a patient, isolating a mixture of protein components of urine and blood, conducting an enzyme immunoassay reaction with monoclonal and / or polyclonal antibodies and / or fragments thereof against recombinant protein UBE2C and / or its unique fragments with a length of more than 8 amino acids and conducting diagnostics by determining the content of UBE2C protein in the studied samples.

Claims (3)

1. Способ диагностики рака мочевого пузыря методом ПЦР в режиме реального времени, включающий получение биоматериала и выделение РНК, синтез кДНК на матрице РНК, нормирование концентрации кДНК UBE2C по контрольному гену, проведение количественной ПЦР-амплификации фрагмента гена UBE2C и проведение диагностики путем определения количества амплифицированного фрагмента ДНК UBE2C для образца биоматериала.1. A method for the diagnosis of bladder cancer by real-time PCR, including biomaterial production and RNA isolation, cDNA synthesis on an RNA matrix, normalization of the concentration of UBE2C cDNA by the control gene, quantitative PCR amplification of a fragment of the UBE2C gene and diagnosis by determining the amount of amplified UBE2C DNA fragment for a biomaterial sample. 2. Набор для диагностики рака мочевого пузыря по п.1 методом ПЦР в реальном времени, включающий праймеры с последовательностью SEQ ID NO: 1 и 2 при их молярном соотношении 1:1.2. The kit for the diagnosis of bladder cancer according to claim 1 by real-time PCR, including primers with the sequence of SEQ ID NO: 1 and 2 with a molar ratio of 1: 1. 3. Способ диагностики рака мочевого пузыря методом иммуноферментного анализа, включающий получение образцов мочи и крови от пациента, выделение смеси белковых компонентов мочи и крови, проведение реакции иммуноферментного анализа с моноклональными и/или поликлональными антителами и/или их фрагментами против рекомбинантного белка UBE2C и/или его уникальных фрагментов длиной свыше 8 аминокислот и проведение диагностики путем определения содержания белка UBE2C в исследуемых образцах. 3. A method for the diagnosis of bladder cancer by enzyme immunoassay, which includes obtaining urine and blood samples from a patient, isolating a mixture of protein components of urine and blood, conducting an enzyme immunoassay reaction with monoclonal and / or polyclonal antibodies and / or fragments thereof against recombinant protein UBE2C and / or its unique fragments with a length of more than 8 amino acids and conducting diagnostics by determining the content of UBE2C protein in the studied samples.
RU2011109880/10A 2011-03-16 2011-03-16 Method of estimating efficiency of therapy urinary bladder cancer in humans by method of immunofermentative analysis RU2468088C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2011109880/10A RU2468088C1 (en) 2011-03-16 2011-03-16 Method of estimating efficiency of therapy urinary bladder cancer in humans by method of immunofermentative analysis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011109880/10A RU2468088C1 (en) 2011-03-16 2011-03-16 Method of estimating efficiency of therapy urinary bladder cancer in humans by method of immunofermentative analysis

Publications (2)

Publication Number Publication Date
RU2011109880A true RU2011109880A (en) 2012-09-27
RU2468088C1 RU2468088C1 (en) 2012-11-27

Family

ID=47077900

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011109880/10A RU2468088C1 (en) 2011-03-16 2011-03-16 Method of estimating efficiency of therapy urinary bladder cancer in humans by method of immunofermentative analysis

Country Status (1)

Country Link
RU (1) RU2468088C1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111323585A (en) * 2020-02-27 2020-06-23 北京健平金星生物科技有限公司 Preparation method of nuclear matrix protein 22 enzyme-linked immunoassay kit and kit

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2641170C1 (en) * 2017-08-15 2018-01-16 Олег Борисович Лоран Method for bladder cancer course prediction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111323585A (en) * 2020-02-27 2020-06-23 北京健平金星生物科技有限公司 Preparation method of nuclear matrix protein 22 enzyme-linked immunoassay kit and kit

Also Published As

Publication number Publication date
RU2468088C1 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
RU2663724C2 (en) Methods for determining patient's susceptibility to nosocomial infection and predicting development of a septic syndrome
Shiiki et al. Association between saliva PSA and serum PSA in conditions with prostate adenocarcinoma
DE602006012995D1 (en) BREAST CANCER DIAGNOSTIC PROCEDURE
RU2013113314A (en) METHODS FOR IDENTIFICATION OF ANTIBODIES AGAINST HE4 AND METHODS FOR DIAGNOSTIC AND / OR FORECASTING CONDITIONS ASSOCIATED WITH EXPRESS HE4 CELLS
JP2013536442A5 (en)
WO2018210201A1 (en) Molecular marker, kit and application for use in early diagnosis and prediction of sepsis as complication of acute kidney injury
WO2012163263A1 (en) Reagents and methods for prrsv detection
JP2008523398A (en) CD99 as a target / marker of insulin resistance
EP1951891A4 (en) Cancer antigen mage-a9 and uses thereof
EP3998273A1 (en) Methods for using exosomes to monitor transplanted organ status
CN113684317B (en) Ultra-sensitive rapid detection and identification system for B type and C type hepatitis B virus based on CRISPR-Cas12B
CN111217912B (en) Antibody against PG II and application thereof
ES2633732T3 (en) Procedure and kit to determine in vitro the immune status of an individual
RU2011109880A (en) METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING THE ONBECOMMARKER UBE2C (OPTIONS) AND KIT FOR ITS IMPLEMENTATION
RU2011109883A (en) DIAGNOSIS METHOD FOR BLADDER CANCER USING THE KIFC1 ONCOM MARKER (OPTIONS) AND KIT FOR ITS IMPLEMENTATION
CN109709328B (en) Diagnostic marker for ovarian cancer and application thereof
RU2011109882A (en) METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING THE ONCOMARKER ATR6V1C1 (OPTIONS) AND KIT FOR ITS IMPLEMENTATION
KR102525734B1 (en) Arteriosclerosis and cancer detection method using deoxyhypusine synthase gene as indicator
RU2011109879A (en) METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING ONCOM MARKER PRC1 (OPTIONS) AND KIT FOR ITS IMPLEMENTATION
CN108715848A (en) Applications of the transcription factor CEBP α as the transcription factor of Kiss1 promoter regions
JP2012503634A5 (en)
RU2011103094A (en) METHOD FOR DIAGNOSTIC OF BLADDER CANCER (OPTIONS) AND KIT FOR ITS IMPLEMENTATION
RU2011109878A (en) METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING THE NUSAPI ONCOMARKER (OPTIONS) AND KIT FOR ITS IMPLEMENTATION
US20150219662A1 (en) Use of protein line-1 orf-1 as a biomarker for cancer
CN104450712B (en) The sequence of oligonucleotides aglucon V4 2 of specific recognition Vasorin (VASN) albumen a kind of and application

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160317